長距離マルチオミクスは,イライラ性腸症候群の根底にあるサブセット特有のメカニズムを明らかにします
Ruben A T Mars1, Yi Yang2, Tonya Ward3
1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.
Cell
|September 11, 2020
まとめ
刺激性腸症候群 (IBS) の腸内微生物群の調査により,サブタイプ特有の微生物および代謝の変化が明らかになった. マルチオミクスのデータを統合することで,IBSの新たな治療目標として,ピューリン代謝が特定されました.
科学分野:
- 胃腸内科
- 微生物群の研究
- システム生物学
背景:
- 刺激性腸症候群 (IBS) などの慢性胃腸疾患における腸内微生物の役割は認められているが,その仕組みの理解は限られている.
- 動物とヒトの研究の不一致や 統合されたマルチオミックスのデータ不足が課題です
- 病気特有の生理学的変化を理解するには 総合的なアプローチが必要です
研究 の 目的:
- IBS患者における縦断的なマルチオミックデータ (微生物群,代謝群,表遺伝子群,転写群) を統合する.
- IBSサブタイプに特有の微生物と宿主の生理学的変化を特定する.
- IBSの治療の可能性のある新しい宿主-微生物の代謝経路を発見する.
主な方法:
- 腸内マイクロバイオーム,メタボローム,宿主エピジェノーム,およびトランスクリプトームからの縦断的なマルチオミックデータ統合.
- 微生物の組成,機能,代謝物の変化の分析
- IBSに関連する宿主の生理学的メカニズムとの微生物の変化の相関関係.
主要な成果:
- 腸内微生物の組成と機能における特定されたIBSサブタイプと症状に関連する変化
- IBSに関連する宿主生理学的メカニズムに関連した特定の微生物代謝産物
- IBSに関与する新しい宿主-微生物経路として purin代謝を発見した.
結論:
- 統合されたマルチオミックデータと縦断サンプル採取は,慢性腸胃疾患の機能的メカニズムを明らかにするために不可欠です.
- 特定された purin 代謝経路は,IBS の潜在的な治療目標です.
- このアプローチは慢性的な消化器疾患の総合的な治療戦略に役立ちます.
関連する概念動画
01:17Irritable Bowel Syndrome I: Introduction
768
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
768
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
588
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
588
01:17Chronic Bowel Disorders: Introduction
666
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
666
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
535
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
535
01:17Drugs for Treatment of Diarrhea-Predominant IBS
493
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
493
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
682
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
682